Skip to main content
. 2019 Nov 21;19:196. doi: 10.1186/s12876-019-1110-1

Fig. 5.

Fig. 5

Clinical remission and response rates of the GMA therapy in patients with UC and CD in special situation. CD Crohn’s disease, GMA granulocyte and monocyte adsorptive apheresis, UC ulcerative colitis